[Prevention of post-transfusion non-A, non-B hepatitis by anti-HCV screening].
Since May 1990 a specific enzyme immunoassay (EIA) for NANBH has been developed by recombinant DNA technology which detects antibodies to a virus called hepatitis C virus (HCV). The anti-HCV EIA was manufactured by Ortho-Diagnostic Systems with recombinant antigens from Chiron Corp. based on extraction from high infectious titre chimpanzee plasma RNA after transcription into cDNA. We tested the anti-HCV prevalence of blood donors and hemodialysis patients. The anti-HCV prevalence with the first generation test was 0.52% (Ortho), 0.87% (Abbott) in blood donors and 4.16% in hemodialysis patients. The second generation anti-HCV test (Abbott) with improved sensitivity and specificity comprises 0.25% repeated anti-HCV positive blood donors and 8.2% anti-HCV positive hemodialysis patients.
Holzberger
G
G
Inst. f. Immunhämatologie, Univ. Frankfurt, BRD.
Seidl
S
S
Peschke
B
B
Scheuermann
E H
EH
Schoeppe
W
W
D000956:Antigens, Viral / Q000276:immunology*; D001782:Blood Donors; D001803:Blood Transfusion; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000032:analysis*; D006526:Hepatitis C / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D018936:Hepatitis C Antigens; D006801:Humans; D006435:Renal Dialysis; D012307:Risk Factors
D000956:Antigens, Viral; D006508:Hepatitis Antibodies; D018936:Hepatitis C Antigens